Management options in advanced prostate cancer: What is the role for sipuleucel-T?

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 325-332

  Bitting, Rhonda L ^a   Armstrong, Andrew J ^a   George, Daniel J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Abiraterone acetate; Cabazitaxel; Castration resistant prostate cancer; Chemotherapy; Sipuleucel T

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; CORTICOSTEROID; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE; IPILIMUMAB; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; ZIBOTENTAN; ZOLEDRONIC ACID;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILL; DOSE RESPONSE; DRUG APPROVAL; DRUG DEPENDENCE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GLAUCOMA; GLUCOSE INTOLERANCE; HEADACHE; HEALTH CARE ACCESS; HUMAN; HYPERTENSION; LOW DRUG DOSE; MELANOMA; METASTASIS; MYALGIA; OVERALL SURVIVAL; PEPTIC ULCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; TREATMENT INDICATION; WEIGHT GAIN;

EID: 80455123840     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S5977     Document Type: Review

References (25)

1. Jemal A, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5): 277-300.
2. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 2005;15(3):181-6.
3. Petrylak DP, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20.
4. Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus predni-sone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12.
5. Kantoff PW, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
6. de Bono J.S, et al. Prednisone plus cabazitaxel or mitoxantrone for meta-static castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.
7. de Bono JS, et al. Abiraterone acetate plus low dose prednisone improves survival in patients with metastatic castration resistant prostate cancer who have progressed after docetaxel-based chemotherapy: Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. ESMO annual meeting, Milan, Italy, 2010(Abstract LBA5).
8. Tannock IF, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996; 14(6):1756-64.
9. Kantoff PW, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17(8):2506-13.
10. Scher HI, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol. 2011;29(suppl; abstr LBA4517).
11. Small EJ, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089-94.
12. Higano CS, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670-9.
13. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
14. Hoos A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102(18):1388-97.
15. Hall SJ, Integrated safety results from 4 randomized, double-blind, placebo-controlled studies of sipuleucel-T, in 105th American Urological Association Meeting. 2010: San Francisco, California.
16. George DJ, et al. Subsequent treatment with APC8015F and its effect on survival in the control arm of phase III sipuleucel-t studies. J Clin Oncol. 2011;29(suppl 7; abstr 139).
17. Smith MR, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23(13): 2918-25.
18. Yu EY, Nathan FE, Higano CS. Role of detection of metastatic disease as a leading cause of screening failure in an ongoing phase III trial of zibotentan versus placebo in patients with nonmetastatic castration-resistant prostate cancer (CRPC). J Clin Oncol. 2011;29(suppl 7; abstr 135).
19. Armstrong AJ, et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010;46(3):517-25.
20. Saad F, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-68.
21. Fizazi K, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 2011;377(9768):813-22.
22. Tannock I, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989;7(5):590-7.
23. Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abi-raterone acetate, confrms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563-71.
24. Hinrichs CS, et al. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother. 2005;28(6):517-24.
25. Proposed decision memo for autologous cellular immunotherapy treatment of metastatic prostate cancer (CAG-00422 N), in Centers for Medicare and Medicaid Services. March 30, 2010.